Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: A review

Annals of the New York Academy of Sciences

Volumn 1033, Issue , 2004, Pages 79-91

  Ferrari, Roberto ^a,b   Merli, E ^a   Cicchitelli, G ^a   Mele, D ^a   Fucili, A ^a   Ceconi, C ^a  

^a ENT and Audiology Department University Hospital of Ferrara   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Levocarnitine; Myocardial ischemia; Myocardial metabolism; Propionyl L carnitine

Indexed keywords

ACETYL COENZYME A; CARNITINE; COENZYME A; LACTIC ACID; PROPIONYLCARNITINE; PYRUVATE DEHYDROGENASE; VALPROIC ACID;

ANTIANGIOGENIC ACTIVITY; CARDIOVASCULAR DISEASE; CARNITINE DEFICIENCY; CITRIC ACID CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; EXERCISE; HEART ATRIUM PACING; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HEMODIALYSIS; HIGH ENERGY PHOSPHATE; HUMAN; ISCHEMIA; KIDNEY FAILURE; LIVER TOXICITY; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; MUSCLE METABOLISM; REPERFUSION INJURY; ST SEGMENT DEPRESSION; SUPPLEMENTATION;

EID: 10644296223     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1320.007     Document Type: Conference Paper

References (84)

1. DE VIVO, D.C. & I. TEIN. 1990. Primary and secondary disorders of carnitine metabolism. Int. Pediatr. 5: 134-141.
2. LOPASCHUK, G.D. 1991. Current Concepts in Carnitine Research, pp. 1-5. Atlanta.
3. LIEDTKE, A.J., H. NELLIS & L.F. WHITESELL. 1981. Effects of carnitine isomers on fatty acid metabolism in ischemic swine hearts. Circ. Res. 48: 859-866.
4. LIEDTKE, A.J., H. NELLIS, L.F. WHITESELL & C.Q. MAHAR. 1982. Metabolic and mechanical effects using L- and D-carnitine in working swine hearts. Am. J. Physiol. 243: H691-H697.
5. ANGELINI, C., L. VERGANI, L. COSTA et al. 1986. Clinical study of efficacy of L-carnitine and metabolic observations in exercise physiology. In Clinical Aspects of Human Carnitine Deficiency, p. 38. Pergamon. New York.
6. MARCONI, C., G. SASSI, A. CARPINELLI & P. CERRETELLI. 1985. Effects of L-carnitine loading on the aerobic and anaerobic performance of endurance athletes. Eur. J. Appl. Physiol. 54: 131-135.
7. THOMSEN, J.H., A.L. SHUG, V.U. YAP et al. 1979. Improved pacing tolerance of the ischemic human myocardium after administration of carnitine. Am. J. Cardiol. 43: 300-306.
8. FERRARI, R., F. CUCCHINI & O. VISIOLI. 1984. The metabolic effects of L-carnitine in angina pectoris. Int. J. Cardiol. 5: 213-216.
9. REFORZO, G., P.L. DE ANDREIS BESSONE, F. REBAUDO & M. TIBALDI. 1986. Effects of high doses of L-carnitine on myocardial lactate balance during pacing-induced ischemia in aging subjects. Curr. Ther. Res. 40: 374-383.
10. ROSSI, C.S. & N. SILIPRANDI. 1982. Effect of carnitine on serum HDL-cholesterol: report of two cases. Johns Hopkins Med. J. 150: 51-54.
11. POLA, P., P. TONDI, A. DAL LAGO et al. 1983. Statistical evaluation of long-term L-carnitine therapy in hyperlipoproteinaemias. Drugs Exp. Clin. Res. 12: 925-935.
12. KAMIKAWA, T., Y. SUZUKI, A. KOBAYASHI et al. 1984. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn. Heart J. 25: 587-597.
13. KOLOLCHAROEN, P., J. NAPPI, P. PEDUZZI et al. 1981. Improved exercise tolerance after administration of carnitine. Curr. Ther. Res. 30: 753-764.
14. CANALE, C., V. TERRACHINI, A. BIAGINI et al. 1988. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: semiautomatic computerized analysis of M-mode tracings. Int. J. Clin. Pharmacol. Ther. Toxicol. 26: 221-224.
15. BREVETTI, G., M. CHIARIELLO, G. FERULANO et al. 1988. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 77: 767-773.
16. FDA. 1989. The pink sheet. FDA Reports 51: 7-9.
17. STANLEY, C.A., D.E. HALE & P.M. COATES. 1983. Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr. Res. 17: 877-884.
18. ROE, C.R., D.S. MILLINGTON, D.A. MAITBY et al. 1984. L-Carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. J. Clin. Invest. 73: 1785-1788.
19. CHALMEAR, R.A., R.C. ROE, C.E. STACEY & C.L. HOPPEL. 1984. Urinary excretion of L-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of L-carnitine. Pediatr. Res. 18: 1325-1328.
20. WINTER, S.C., M.Z. ELINOR, H. VANCE et al. 1991. The clinical use of carnitine for the treatment of organic acidurias. Int. Pediatr. 6: 62-65.
21. DURAN, M., D. KETTING, J.E. BECKERING et al. 1986. Direct identification of propionyl-carnitine in propionic acidemia: biochemical and clinical results of oral carnitine supplementation. J. Inherited Metab. Dis. 9: 202-207.
22. SECCOMBE, D.W., F. SNYDER & H.G. PARSONS. 1982. L-Carnitine for methylmalonic aciduria. Lancet 1982: 1401.
23. LESCHKE, M., K.W. RUMPF, T. EISENHAUER et al. 1983. Quantitative assessment of carnitine loss during hemodialysis and hemofibrillation. Kidney Int. 24: 143-146.
24. BELLINGHIERI, G., V. SAVICA, A. MALLAMA et al. 1983. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am. J. Clin. Nutr. 38: 523-531.
25. ALBERTAZZI, A., P. CAPELLI, B. DI PAOLO et al. 1982. Endocrine metabolic effects of L-carnitine in patients on regular dialysis treatment. Proc. EDTA 19: 302-307.
26. DI MARCO, V., V. GINARDI, E. DELL'SIRA et al. 1982. La carnicina nel trattamento dei crampi muscolari nei pazienti in emodialisi periodica. Policlinico, Sezione Medica 89: 104-110.
27. AUBIA, J., J. MASRAMON, J. LHOVERAS et al. 1980. Carnitine in haemodialysis patients. Lancet 1980: 1028.
28. CASCIANI, C.V., U. CARUSO, E. CRAVOTTO et al. 1982. Beneficial effects of L-carnitine in post-dialysis syndrome. Curr. Ther. Res. 32: 116-126.
29. AHMAD, S., H.T. ROBERTSON, T.A. GOLPER et al. 1990. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 38: 912-918.
30. SUZUKI, Y., M. NARITA & N. YAMAKAZI. 1982. Effects of L-carnitine on arrhythmias during hemodialysis. Jpn. Heart J. 23: 349-358.
31. TROVATO, G.M., V. GINARDI, V. DI MARCO et al. 1987. Long-term carnitine treatment of chronic anemia of patients with end-stage renal failure. Curr. Ther. Res. 31: 1042-1049.
32. VACHA, G.M., G. GIOCELLI, N. SILIPRANDI & M. CORSI. 1983. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. Am. J. Clin. Nutr. 38: 532-540.
33. OHTANI, Y., F. ENDO & I. MATSUDA. 1980. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J. Pediatr. 101: 782-785.
34. DREIFFUS, F.E., N. SANTILLI, D.H. LANGER et al. 1987. Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379-385.
35. BRATTON, S.L., A.L. GARDEN, T.P. BOHAN et al. 1992. A child with valproic acid-associated carnitine deficiency and carnitine-responsive cardiac dysfunction. J. Child Neurol. 7: 413-416.
36. CASTRO-CAGO, M., I. NOVO & S. RODRIGUEZ-SEGADE. 1990. Effects of valproic acid on the urea cycle and carnitine metabolsim. Int. Pediatr. 5: 54-57.
37. SUGIMOTO, T., N. NISHIDA, K. MURAKAMI et al. 1990. Valproate-induced hepatotoxicity: protective effect of L-carnitine supplementation. Jpn. J. Psychiatry Neurol. 44: 387-388.
38. SPAGNOLI, L.G., M. CORSI, S. VILLASCHI et al. 1982. Myocardial carnitine deficiency in acute myocardial infarction. Lancet 1982: 1419-1420.
39. SUZUKI, Y. 1982. Myocardial carnitine deficiency in chronic heart failure. Lancet 1982: 116.
40. PEPINE, C.J. 1992. The therapeutic potential of carnitine in cardiovascular disorders. Clin. Ther. 13: 3-22.
41. RIZZON, P., C. BIASCO & F. BOSCIA. 1989. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur. Heart J. 10: 502-508.
42. ILICETO, S., D. SCRUTINIO, P. BRUZZI et al. 1995. Effects of L-carnitine administration on left ventricular remodelling after acute anterior myocardial infarction (the CEDIM trial). J. Am. Coll. Cardiol. 26: 380-387.
43. BREVETTI, G., M. CHIARIELLO, G. FERULANO et al. 1988. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double blind, cross-over study. Circulation 77: 767-773
44. CEVESE, A., F. SCHENA & G. CEROTTI. 1989. Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiologia 34: 95-101.
45. CEVESE, A., F. SCHENA & G. CERUTTI. 1991. Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiovasc. Drugs Ther. 5(suppl. II): 45-56.
46. CHIDDO, A., S. MUSCI, A. BORTOME et al. 1989. Effetti emodinamici e sul circolo coronarico della propionyl-L-carnitina. Cardiologia 54(suppl. 1): 111-117.
47. CHIDDO, A., A. GAGLIONE, S. MUSCI et al. 1991. Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function. Cardiovasc. Drugs Ther. 5(suppl. I): 107-112.
48. TASSANI, V., L. CATTAPAN, L. MAGNANIMI et al. 1994. Anaplerotic effect of propionyl-L-carnitine in rat heart mitochondria. Biochem. Biophys. Res. Commun. 199: 949-953.
49. ZWEIER, J.L. & E. JACOBUS. 1987. Substrate-induced alteration of high energy phosphate metabolism and contractile function in the perfused heart. J. Biol. Chem. 262: 8015-8021.
50. FERRARI, R., F. DI LISA, J.W. DE JONG et al. 1992. Prolonged propionyl-L-carnitine pretreatment of rabbit: biochemical, hemodynamic, and electrophysiological effects on myocardium. J. Mol. Cell. Cardiol. 24: 219-232.
51. BARBIERI, M., P.U. CARBONIN, E. CERBAI et al. 1991. Lack of correlation between the antiarrhythmic effect of L-propionylcarnitine on reoxygenation-induced arrhythmias and its electrophysiological properties. Br. J. Pharmacol. 102: 73-78.
52. FERRARI, R., E. PASINI, E. CONDORELLI et al. 1991. Effect of propionyl-L-carnitine on mechanical function of isolated rabbit heart. Cardiovasc. Drugs Ther. 5: 17-24.
53. FERRARI, R., A. CARGNONI, C. CECONI et al. 1990. Effect of L-carnitine derivatives on lipid peroxidation of cardiac mitochondria. Soc. Ital. Biochim. 2: 200.
54. NOBLE, D. 1984. The surprising heart: a review of recent progress in cardiac electrophysiology. J. Physiol. 353: 1-50.
55. BRODERICK, T.L., H.A. QUINNEY, C.C. BARKER et al. 1993. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87: 972-981.
56. LEIPALA, J.A., R. BHATNAGAR, E. PINEDA et al. 1991. Protection of the reperfused heart by L-propionylcarnitine. J. Appl. Physiol. 71: 1518-1522.
57. PAULSON, D.J., J. TRAXLER, M. SCHMIDT et al. 1986. Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc. Res. 20: 536-541.
58. YANG, X.P., M. SAMAJA, E. ENGLISH et al. 1992. Haemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure overload cardiac hypertrophy. J. Cardiovasc. Pharmacol. 20: 88-98.
59. MICHELETTI, R., G. GIACALONE, M. CANEPARI et al. 1994. Propionyl-L-carnitine prevents myocardial mechanical alterations due to pressure overload in rats. Am. J. Physiol. 266: H2190-H2197.
60. MICHELETTI, R., A. SCHIAVONE, E. ENGLISH et al. 1993. Propionyl-L-carnitine limits chronic ventricular dilatation after myocardial infarction in rats. Am. J. Physiol. 264: H1111-H1117.
61. LI, P., R. MICHELETTI, C. PARK et al. 1994. Propionyl-L-carnitine ameliorates myocyte performance after infarction [abstract]. Can. J. Cardiol. 10: 85.
62. PASINI, E., L. COMINI, R. FERRARI et al. 1992. Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Am. J. Cardiovasc. Pathol. 4: 216-222.
63. LOPASCHUCK, G.D., A.G. TAHILIANI, R.V.S.U. VADLAMUDI et al. 1983. Cardiac sarcoplasmic reticulum in insulin- or carnitine-treated diabetic rats. Am. J. Physiol. 245: H969-H976.
64. WILSON, J.R., J.L. MARTIN, D. SCHWARTZ et al. 1984. Exercise intolerance in patients with chronic heart failure: role of impaired skeletal muscle nutritive flow. Circulation 69: 1079-1087.
65. LIPKIN, D.P. & F.A. POOLE-WILSON. 1986. Symptoms limiting exercise in chronic heart failure. BMJ 292: 1030-1031.
66. WILSON, J.R. & M.D. MANCINI. 1993. Factors contributing to exercise limitation of heart failure. J. Am. Coll. Cardiol. 22: 93A-98A.
67. CLARK, A.L., F.A. POOLE-WILSON & A.J.S. COATS. 1996. Exercise limitation in chronic heart failure: central role of the periphery. J. Am. Coll. Cardiol. 28: 1092-1102.
68. SULLIVAN, M.J., J.D. KNIGHT, M.B. HIGGINBOTHAM et al. 1989. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Circulation 80: 769-781.
69. FERRARI, R., E. PASINI, F. DE GIULI et al. 1994. Limb uptake of substrate in patients with congestive heart failure (CHF) [abstract]. Can. J. Cardiol. 10(suppl. A): 73A.
70. OPASICH, C., E. PASINI, R. AQUILANI et al. 1997. Skeletal muscle function at low work level as a model for daily activities in patients with chronic heart failure. Eur. Heart J. 18: 1626-1631.
71. BREVETTI, G., M. CHIARIELLO, G. FERULANO et al. 1988. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double blind, cross-over study. Circulation 77: 767-783.
72. TAYLOR, D.J., A. AMATO, U. HANDS et al. 1996. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31 pMRS: a phase II open study. Vasc. Med. 1: 241-245.
73. BREVETTI, G., S. PERNA, C. SABBÀ et al. 1995. Propionyl-L- carnitine in intermittent claudication: double-blind, placebo-controlled, dose-titration, multicenter study. J. Am. Coll. Cardiol. 26: 1411-1416.
74. HIATT, W.R., J.G. REGENSTEINER, M.A. CREAGER et al. 2001. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am. J. Med. 110: 616-622.
75. BREVETTI, G., C. DIEHM & D. LAMBERT. 1999. European multicenter study on propionyl-L-carnitine in intermittent claudication. J. Am. Coll. Cardiol. 34: 1618-1624.
76. ANAND, I., Y. CHANDRASHEKAR, F. DE GIULI et al. 1998. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc. Drugs Ther. 12: 291-299.
77. CAPONNETTO, S., C. CANALE, M.A. MASPERONE et al. 1994. Efficacy of L-propionyl-carnitine treatment in patients with left ventricular dysfunction. Eur. Heart J. 15: 1167-1173.
78. MANCINI, M., S. RENGO, M. LINGETTI et al. 1992. Control study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneim. Forsch. 42: 1101-1104.
79. BACHETTI, T., A. CORTI, G. CASSANI et al. 1994. Cytokines in end stage congestive heart failure: effect of propionyl-L-carnitine. Eur. Heart J. 15: 1267-1273.
80. FERRARI, R., T. BACHETTI, R. CONFORTINI et al. 1995. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92: 1479-1486.
81. FERRARI, R. 1998. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc. Res. 37: 554-559.
82. AGNOLETTI, L., S. CURELLO, T. BACHETTI et al. 1999. Serum from patients with severe heart failure downregulates enol and is proapopiotic - role of tumor necrosis factor-α. Circulation 100: 1983-1991.
83. LEVINE, B., J. KALMAN, L. MAYER et al. 1991. Elevated circulating level of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323: 236-241.
84. THE INVESTIGATORS OF THE STUDY ON PROPIONYL-L-CARNITINE IN CHRONIC HEART FAILURE. 1999. Study on propionyl-L-carnitine in chronic heart failure. Eur. Heart J. 20: 70-76.